Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
23 12 2022
Historique:
received: 11 01 2022
revised: 19 04 2022
pubmed: 29 4 2022
medline: 28 12 2022
entrez: 28 4 2022
Statut: ppublish

Résumé

To assess the characteristics and risk of lymphoma in a large cohort of patients with SLE. A case-cohort analysis was performed within a dynamic cohort of SLE patients from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Clinical and analytical features were compared between the lymphoma SLE group and the control SLE group using an independent-sample Student's t-test or Mann-Whitney test for continuous variables and the χ2 test for categorical variables with Fisher's exact test if necessary. The multivariate analysis was based on a generalized linear model. Twenty-one patients with SLE and lymphoma and 3965 non-lymphoma controls with SLE were studied. Most lymphomas were of B cell origin (n = 15/21), with diffuse large B cell lymphoma being the most frequent histological type (8/21, 38.1%). As in the general population, the risk of lymphoma in SLE was higher in male than in female patients and increased with age. In the lymphoma SLE group, bivariate analysis showed a significantly higher percentage of pericarditis, organic brain syndrome, seizures, vasculitis, haemolytic anaemia, splenomegaly, venous thrombosis and mean modified (excluding lymphoma) SLICC/ACR damage index. In contrast, renal involvement, positive anti-dsDNA, and antimalarials ever were less frequent. In this large multicentre Spanish cohort, we identified characteristics of SLE that are associated with a higher risk of lymphoma. Antimalarials were significantly negatively associated with risk of lymphoma in SLE patients. Nevertheless, further prospective studies are needed to clarify these findings.

Identifiants

pubmed: 35482477
pii: 6575422
doi: 10.1093/rheumatology/keac258
doi:

Substances chimiques

Antimalarials 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217-224

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

María Martín-López (M)

Rheumatology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid.

Maria Galindo (M)

Rheumatology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid.

José María Pego-Reigosa (JM)

Rheumatology Department, Hospital do Meixoeiro, Vigo, Galicia.

Norman Jiménez (N)

IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute (IISGS), Vigo.

Alejandro Olivé Marqués (A)

Rheumatology Department, Hospital Universitario Germans Trías i Pujol, Badalona.

Eva Tomero (E)

Rheumatology Department, Hospital Universitario La Princesa, Madrid.

Mercedes Freire (M)

Rheumatology Department, Complejo Hospitalario Universitario A Coruña, A Coruña.

Julia Martínez-Barrio (J)

Rheumatology Department, Hospital Universitario Gregorio Marañón.

Alina Boteanu (A)

Rheumatology Department, Hospital Universitario Ramon y Cajal, Madrid.

Eva Salgado-Perez (E)

Rheumatology Department, Complejo Hospitalario de Orense, Orense, Galicia.

Antonio Fernández-Nebro (A)

Rheumatology Department, Hospital Regional Universitario de Málaga, Málaga.

Jaime Calvo (J)

Rheumatology Department, Hospital Universitario de Araba, Vitoria.

Raul Menor-Almagro (R)

Rheumatology Department, Hospital de Jerez, Cádiz.

Iñigo Rúa-Figueroa (I)

Rheumatology Department, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH